Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Vial of the ChadOx (ChAdOx1 nCoV-2019) vaccine. Photo credit: John Cairns © John Cairns
  • Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
  • In the two different dose regimens vaccine efficacy was 90% in one and 62% in the other
  • Higher efficacy regimen used a halved first dose and standard second dose
  • Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections
  • There were no hospitalised or severe cases in anyone who received the vaccine
  • Large safety database from over 24,000 volunteers from clinical trials in the UK, Brazil and South Africa, with follow up since April
  • Crucially, vaccine can be easily administered in existing healthcare systems, stored at ‘fridge temperature’ (2-8 °C) and distributed using existing logistics
  • Large scale manufacturing ongoing in over 10 countries to support equitable global access

Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:

‘These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regimen is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.’

Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said:

‘The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2. We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for the whole world.’ 

Further information is available on the University of Oxford website

Similar stories

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Oxford’s researchers on the frontline

Coronavirus COVID-19

We rightly hear a lot about Oxford’s vaccine, Covid-19 research and RECOVERY drug trials, but there are also countless personal stories, which display just how broad Oxford’s response to the pandemic has been. It is the contribution and commitment of many individuals that has enabled Oxford’s Medical Sciences Division to become a global leader.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.

Transplant kidney survival rate improves with new method of transportation

Publication Research

New research by the Consortium for Organ Preservation in Europe (COPE) has found that a new method to transport donor kidneys, which uses a combination of cold perfusion with oxygen, can significantly improve transplant results, with less graft failure, better function and lower rejection of the kidney when compared to cold perfusion alone. For patients who need a kidney transplant this is a big step forward. The study, carried out in Belgium, The Netherlands and the UK, was published today in The Lancet.